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NF-B is constitutively activated in chronic lymphocytic leukemia (CLL); however, the 
implicated molecular mechanisms remain largely unknown. Thus, we performed targeted 
deep sequencing of 8 core complex genes within the NF-B pathway in a discovery and 
validation CLL cohort totaling 35 cases. The most frequently mutated gene was NFKBIE 
(2/35 cases; 7%), which encodes IB, a negative regulator of NF-B in normal B cells. 
Strikingly, 3 of these cases carried an identical 4-bp frameshift deletion, resulting in a 
truncated protein. Screening of an additional 377 CLL cases revealed that NFKBIE aberra-
tions predominated in poor-prognostic patients and were associated with inferior outcome. 
Minor subclones and/or clonal evolution were also observed, thus potentially linking this 
recurrent event to disease progression. Compared with wild-type patients, NFKBIE-deleted 
cases showed reduced IB protein levels and decreased p65 inhibition, along with in-
creased phosphorylation and nuclear translocation of p65. Considering the central role of  
B cell receptor (BcR) signaling in CLL pathobiology, it is notable that IB loss was enriched 
in aggressive cases with distinctive stereotyped BcR, likely contributing to their poor prog-
nosis, and leading to an altered response to BcR inhibitors. Because NFKBIE deletions were 
observed in several other B cell lymphomas, our findings suggest a novel common mecha-
nism of NF-B deregulation during lymphomagenesis.
© 2015 Mansouri et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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CLL patients (Table S2). Sequencing resulted in a mean read 
depth of 656 reads/base and 97% of the targeted coding re-
gions being covered (Table S1). By applying a conservative 
cutoff of >10% for the mutant allele, we identified 26 muta-
tions in 11/18 NF-B genes analyzed within 24/124 (19%) 
CLL patients (Table S3); 16/16 selected mutations were vali-
dated by Sanger sequencing. IB (encoded by NFKBIE) was 
the most frequently mutated, being altered in eight patients 
(6.5%): notably, three/eight patients carried an identical 4-bp 
frameshift deletion in NFKBIE exon 1 (Fig. 1 A). When con-
sidering mutations with a low mutant allele frequency (<10%), 
this 4-bp deletion within NFKBIE was found in eight addi-
tional cases (Table S4).
NFKBIE mutations predominated in CLL cases with un-
mutated Ig heavy variable (IGHV) genes (U-CLL) belonging 
to certain subsets with restricted BcR Igs (stereotyped BcRs), 
for which we and others have reported distinct, subset-biased 
profiles regarding their biological background and clinical 
course (Stamatopoulos et al., 2007; Agathangelidis et al., 2012; 
Strefford et al., 2013; Baliakas et al., 2014). Prompted by this 
observation, we again performed targeted resequencing of 
NF-B genes using HaloPlex technology within a validation 
CLL cohort (n = 191) enriched for cases assigned to poor-
prognostic stereotyped subsets (Tables S5 and S6). We found 
30 mutations in 10/18 NF-B genes analyzed within 28 CLL 
patients; strikingly, 13/30 mutations were in IB with 10/13 
patients carrying the 4-bp NFKBIE deletion (Fig. 1 B and 
Table S7). This deletion was also detected at a low mutant al-
lele frequency (<10%) in 18 additional cases (Table S4).
Because germline DNA was lacking for the vast majority 
of patients (because of the retrospective nature of the study), 
we were limited in our ability to confirm the somatic nature 
of mutations. That said, we could verify that mutations within 
the NFKBIE gene were somatic and not germline variants 
in all cases with available material (Tables S3 and S7). For the 
remaining NF-B mutations, we cannot formally exclude the 
possibility that they are rare germline variants (despite exten-
sive filtering against various SNP databases) and hence de-
cided to focus on NFKBIE, which, importantly, was also the 
most frequently mutated NF-B gene.
Enrichment of NFKBIE aberrations  
in poor-prognostic subsets of CLL
We next developed a GeneScan assay specific for the 4-bp 
NFKBIE deletion and studied 377 additional CLL cases, in-
cluding (a) patients from a population-based cohort (Table S8), 
where U-CLL accounted for 32% of cases, with the remain-
ing cases carrying mutated IGHV genes (M-CLL); (b) pa-
tients with stage B/C disease; and (c) patients assigned to 
stereotyped subsets. Overall, 22 additional NFKBIE-deleted 
patients were identified (Table S9). Collectively, this amounted 
to 43/692 (6.2%) CLL patients carrying NFKBIE aberrations 
(i.e., mutations and/or deletions), of whom 37/43 concerned 
U-CLL. A significant enrichment of NFKBIE aberrations 
was observed in certain poor-prognostic stereotyped CLL 
subsets, especially subset #1 (17/112 cases, 15%) and the less 
Consisting of five members, NFKB1 (p50), NFKB2 (p52), 
RELA (p65), RELB, and c-REL (REL), the NF-B signaling 
pathway regulates many cellular processes, including cell cycle 
progression, differentiation, and apoptosis (Bonizzi and Karin, 
2004). These proteins form homo- and heterodimers that are 
held in the cytoplasm by inhibitor proteins (IB) and func-
tion by activating or suppressing target genes (Bonizzi and 
Karin, 2004). The IBs (, , , , and ) are regulated by the 
IB kinase complex, which when activated, phosphorylates 
the IBs, leading to their degradation; this culminates in the 
translocation of transcription factors to the nucleus. In B cells, 
the canonical NF-B pathway can be activated through numer-
ous upstream signals including B cell receptor (BcR) or TLR 
signaling, whereas the noncanonical pathway is primarily acti-
vated through BAFF receptor–CD40 interaction (Bonizzi and 
Karin, 2004; Hömig-Hölzel et al., 2008).
Deregulated NF-B signaling appears to be particularly 
important in B cell malignancies, with recurrent activating mu-
tations identified in both the canonical and the noncanonical 
NF-B pathways (Compagno et al., 2009; Staudt, 2010; Rossi 
et al., 2013a). In chronic lymphocytic leukemia (CLL), NF-B 
activation is known to be present in virtually all cases (Herishanu 
et al., 2011). That notwithstanding, the extent to which genetic 
aberrations contribute to NF-B activation in CLL remains 
largely unknown except for low-frequency (<3%) mutations in 
BIRC3 (noncanonical NF-B pathway) and MYD88 (TLR 
signaling; Baliakas et al., 2015). Very recently, a recurrent 4-bp 
truncating mutation within the NFKBIE gene, which encodes 
IB, a negative regulator of NF-B in B cells, has been re-
ported as frequent in advanced stage CLL (Damm et al., 2014). 
However, the precise functional impact of this mutation and, 
especially, the extent to which it contributes to constitutional 
NF-B activation in CLL remain unexplored.
To gain insight into these issues, we undertook a com-
bined genetic and functional approach for investigating the 
NF-B signaling pathway in CLL. Taking advantage of Halo-
Plex technology (Agilent Technologies), we designed a tar-
geted gene panel and performed deep sequencing of 18 
members of the NF-B pathway in 315 CLL cases. The most 
striking observation was the finding of the recurrent frame-
shift deletion within the NFKBIE gene that resulted in pro-
found functional consequences. In particular, patients carrying 
this truncating mutation displayed lower IB expression and 
reduced IB–p65 interactions, as well as increased levels of 
phosphorylated p65 and nuclear p50/p65. Because we also 
detected this truncating event in other lymphoma entities, 
our finding implies that the loss of IB may be a common 
mechanism contributing to the sustained survival of malig-
nant B cells, thus also shaping disease evolution and ultimately 
impacting disease progression.
RESULTS AND DISCUSSION
Targeted sequencing identifies NFKBIE  
mutations as a recurrent event in CLL
We performed targeted deep sequencing of 18 NF-B core 
complex genes (Table S1) within a discovery cohort of 124 
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mutations in poor-prognostic stereotyped subset #2 com-
pared with all remaining CLL (44% vs. 5%; Rossi et al., 
2013b; Strefford et al., 2013). This subset-biased distribution 
of genomic aberrations in different poor-prognostic stereo-
typed subsets supports the existence of distinct mechanisms 
underlying clinical aggressiveness in CLL and could perhaps 
result from particular modes of BcR-mediated signaling, which 
could shape the evolution of each individual subset. In other 
words, the enrichment seen in stereotyped subsets might pri-
marily be linked to the particular BcR configuration of each 
subset rather than merely attributed to IGHV gene muta-
tional status.
NFKBIE aberrations are linked to rapid  
disease progression and poor outcome
The presence of NFKBIE aberrations was associated with a 
significantly shorter time to first treatment (TTFT) similar to 
IGHV-unmutated or 17p-deleted patients (Fig. 2 B), which 
was perhaps expected given the preference toward clinically 
aggressive CLL subsets (Stamatopoulos et al., 2007; Baliakas 
et al., 2014). In multivariate analysis including established 
risk factors, NFKBIE aberrations did not hold as an indepen-
dent factor; however, when IGHV mutational status (one of 
the strongest molecular predictors of TTFT in CLL [Baliakas 
et al., 2015]) was removed from the model, NFKBIE aberra-
tions regained significance (Table S10). Taking into account 
that almost all cases with NFKBIE aberrations concerned 
U-CLL, this could be the overarching reason behind this lat-
ter finding, along with the comparatively lower number of 
cases in the NFKBIE-mutated/deleted group (relative to IGHV- 
unmutated CLL). Despite a limited number of cases showing 
populated subset #6 (5/35 cases, 14%; Fig. 1 B), further sup-
porting the concept that the subclassification of CLL based 
on BcR stereotypy may supersede the more generic dis-
crimination into U-CLL or M-CLL (Baliakas et al., 2014). 
A considerably lower frequency of NFKBIE aberrations was 
observed within our population-based cohort (4/236, 1.7%; 
Smedby et al., 2005), whereas advanced stage B/C patients 
carried NFKBIE aberrations at a frequency of 6.1% (12/198), 
thus lower than recently reported (10%; Damm et al., 2014).
In Fig. 2 A, we depict coexisting cytogenetic/molecular 
lesions in the 43 patients with NFKBIE aberrations; al-
though a small proportion of cases carried concomitant poor-
prognostic TP53 (7%), NOTCH1 (14%), and SF3B1 (9%) 
mutations, the majority of cases did not carry mutations 
within these genes. Because mutations have been described 
in two other NF-B pathway genes in CLL, MYD88 and 
BIRC3, albeit at a low frequency (Baliakas et al., 2015), we 
also sequenced the hotspot p.L265P MYD88 mutation and 
exons 6–9 of BIRC3. In total, 4/495 (0.8%) patients carried a 
p.L265P MYD88 mutation, none of which co-occurred with 
a mutation in NFKBIE, whereas 8/568 (1.4%) patients har-
bored mutations within BIRC3, with only 1 of these patients 
carrying the 4-bp deletion within NFKBIE. In addition, we 
analyzed copy number data for 369 CLL cases obtained from 
SNP arrays (250K) and found only 3 cases showing a poten-
tial monoallelic deletion covering the NFKBIE gene (on chro-
mosome 6p21.1); none of these cases had a truncating NFKBIE 
mutation (not depicted).
The remarkable enrichment of NFKBIE aberrations in 
poor-prognostic subset #1 (17/43 NFKBIE-mutated/deleted 
cases, 39.5%) recalls the significantly higher frequency of SF3B1 
Figure . Recurrent aberrations within 
the NFKBIE gene. (A) Schematic representa-
tion of the human IB protein with its key 
functional domains. Color-coded symbols 
depict NFKBIE alterations with a variant allelic 
frequency >10% detected in the discovery 
and validation CLL cohorts using targeted 
deep sequencing. All missense mutations were 
predicted to be damaging by the prediction 
software Polyphen-2. (B) NFKBIE mutation 
frequencies as determined by HaloPlex or 
GeneScan analysis. The total number of tested 
cases included in each category is indicated 
above each bar. Significant differences in 
NFKBIE mutation frequencies between IGHV-
unmutated CLL and selected poor-prognostic 
stereotyped subsets are indicated; a border-
line significant trend was also seen when 
comparing U-CLL with #6 (P = 0.06). * indi-
cates a p-value <0.05. †The only IGHV- 
mutated case carrying a NFKBIE mutation was 
a poor-prognostic subset #2 patient. CLL U, 
IGHV-unmutated CLL; CLL M, IGHV-mutated 
CLL; MCL, mantle cell lymphoma; SMZL, 
splenic marginal zone lymphoma.
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results are highly indicative of a common mechanism for 
NF-B deregulation within at least a subset of mature B cell 
malignancy cases (Fig. 1 B).
IB disruption results in reduced inhibition  
and increased nuclear p65 levels
In normal B cells, IB provides negative regulation upon 
BcR/TLR stimulation by limiting nuclear migration of 
Rel-containing NF-B dimers (e.g., p65 and REL) through 
protein binding via the ankyrin repeat region (Fig. 1 A), thus 
ensuring temporal control of NF-B activation (Alves et al., 
2014). Furthermore, IB loss was reported to result in in-
creased B cell proliferation and survival of stimulated B cells 
in IB/ mice (Alves et al., 2014). To understand the func-
tional consequence of truncating NFKBIE mutations for the 
NF-B signaling pathway in CLL, the three IB members 
(, , and ) were investigated together with the transcription 
factor p65 using Western blot analysis. Significantly lower 
IB protein levels were observed in NFKBIE-deleted (n = 7, 
mean allele frequency 45%, range 28–61%) versus WT patients 
(n = 7; P < 0.001), whereas no differences were detected for 
either IB or IB (Fig. 3, A–C). Accordingly, phosphory-
lated p65 levels were significantly higher in NFKBIE-deleted 
versus WT patients (Fig. 3, A–C; P < 0.05).
The 4-bp frameshift NFKBIE deletion is predicted to 
lead to the introduction of a stop codon and subsequent loss 
of the ankyrin repeat region, thus potentially resulting in a 
truncated form (with a predicted mass of 13.4 kD) lacking 
coexisting TP53, SF3B1, or NOTCH1 aberrations, no other 
clinicobiological factor was identified that could explain the 
poor outcome seen for the vast majority of cases with NFK-
BIE aberrations, thus implying an important role as a driver 
mutation during disease evolution.
Because NFKBIE aberrations were linked to inferior out-
come and considering the finding of low-frequency (<10%) 
4-bp NFKBIE deletions in a considerable proportion of cases 
(Table S4), we also investigated longitudinal samples available 
from 14 treated CLL cases. These cases exhibited varying al-
lele frequencies in the initial sample investigated (8/14 cases 
<10%, range 1–8%), and an increase in the allelic frequency 
of the NFKBIE mutations and/or deletions was observed 
over time and at relapse in 6/14 cases (Fig. 2 C). Such tem-
poral dynamics is indicative of clonal evolution and poten-
tially links these aberrations to disease progression. Admittedly, 
this has to be studied in more detail, in particular because the 
variant allele frequency of several cases with low-frequency 
NFKBIE aberrations was found to remain stable or essentially 
unaltered at relapse.
Considering our findings in CLL and the sparse reporting 
of NFKBIE mutations in other lymphomas (Emmerich et al., 
2003; Gunawardana et al., 2014), we performed a compre-
hensive screening of 372 additional mature B cell lymphomas 
by either targeted sequencing or GeneScan analysis. NFKBIE 
deletions were detected in 7/136 (5.1%) mantle cell lympho-
mas, 3/66 (4.5%) diffuse large B cell lymphomas (DLBCLs), 
and 3/170 (1.8%) splenic marginal zone lymphomas. These 
Figure 2. NFKBIE aberrations and associa-
tions with clinicobiological data. (A) Coexist-
ing cytogenetic/molecular aberrations in 43 
NFKBIE-mutated/deleted cases. (B) TTFT in pa-
tients carrying NFKBIE aberrations, IGHV- 
unmutated/mutated genes, or del(17p).  
(C) Clonal evolution in patients carrying NFKBIE 
aberrations. Dark blue lines indicate samples 
investigated by GeneScan analysis (nine cases), 
whereas green lines indicate samples assessed 
by exome sequencing (five cases). The latter 
analysis also confirmed the somatic origin of 
NFKBIE aberrations (four deletions and one 
SNV). Red arrows indicate time of treatment 
relative to sample collection. In 6/14 cases, 
clones carrying NFKBIE aberrations increased 
over time. From available mutation data on 
TP53, SF3B1, and NOTCH1, only two of these 
cases carried a coexisting TP53 mutation (case 
7 and 14). In case 7, the overall trend and allele 
frequencies for the mutated TP53 subclone 
closely resembled that of the NFKBIE-deleted 
subclone, whereas for case 14, no longitudinal 
data on TP53 was available. CNA, copy number 
aberration; NA, not available.
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p65 using an alternative approach by applying proximity liga-
tion assays, a highly sensitive method for real-time visualiza-
tion of protein–protein interactions in situ (Söderberg et al., 
2006). In six NFKBIE WT CLL cases, although interactions 
were detected for all IBs in unstimulated CLL cells, IB 
exhibited the greatest number of interactions with p65 per 
cell analyzed, supporting its important role in CLL (Fig. 4 C). 
Upon stimulation with IgM or CD40 ligand (CD40L), al-
though the interactions between all IBs and p65 were reduced, 
IB was predominantly affected (Fig. 4, C–F). In contrast, in 
six NFKBIE-deleted cases, IB and p65 interactions in un-
stimulated CLL cells were notably reduced, thus resembling 
stimulated WT cells (Fig. 4, C–F); however, this finding did 
not reach statistical significance (P = 0.15), probably because 
of the low number of cases available for analysis.
Altogether, our data indicates that these truncating mu-
tations reduce IB levels, in turn leading to reduced IB–
p65 interactions, and, consequently, increasing phosphorylated 
p65, which is potentially underlying a more activated state. This 
was further supported by subsequent fractionation experiments 
this domain, which is a prerequisite for binding to p65 (and 
other transcription factors). Although both the mutant and WT 
alleles were expressed at the RNA level in NFKBIE-deleted 
patient samples (Table S11), Western blot analysis for low-
molecular mass proteins did not reveal any truncated form of 
IB in NFKBIE-deleted cases besides that corresponding 
to the WT protein (41 kD; Fig. 3 D). Because the truncated 
form does not appear to render a stable protein, this suggests 
that the NFKBIE deletion may represent a loss-of-function 
mutation. Regarding the other NFKBIE mutations, all of 
which were missense mutations, these were predominantly 
located in the ankyrin domain and were deemed as deleteri-
ous using various prediction tools (Fig. 1 A).
To further explore how the interaction between IB  
and p65 is influenced, coimmunoprecipitation (co-IP) exper-
iments with p65 demonstrated a lower pull-down of IB  
in NFKBIE-deleted (n = 3) versus WT (n = 2) cases (Fig. 4, 
A and B), indicating reduced interaction between IB and 
p65. Seeking further support for the latter finding, we studied 
the physical interaction between IB, IB and IB, and 
Figure 3. Protein expression analysis in 
NFKBIE-deleted versus WT CLL. (A) Protein 
expression profiles of IB, IB and IB, 
p65, and phospho-p65 in NFKBIE-deleted (n = 4) 
versus WT (n = 4) CLL by Western blot analy-
sis. (B) Protein expression profiles of IB, 
IB and IB, p65, and phospho-p65 in 
additional NFKBIE-deleted (n = 3) versus WT 
(n = 3) CLL by Western blot analysis. (C) Mean 
normalized protein expression values for IB, 
IB and IB, p65, and phospho-p65 in 
NFKBIE-deleted (n = 7) versus WT CLL (n = 7). 
* indicates P < 0.05, whereas *** indicates  
P < 0.001. For IB, only four NFKBIE-deleted 
and four WT CLL cases were assessed. Error 
bars indicate standard error. (D) Western blot 
analysis of IB in CLL to identify the presence 
of a truncated IB protein. The membrane is 
overexposed. del, deleted.
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45%, range 28–61%) and nine WT patients. Although an in-
teresting up-regulation of several small nuclear RNAs (i.e., 
SNORD66, SNORD114-1, and SNORA80-B), previously 
linked to cancer (Gao et al., 2015), was observed in the NFKBIE-
deleted group, only a few genes were significantly differentially 
expressed between the subgroups (Table S14). This finding 
might reflect previous gene expression profiling studies in 
U-CLL and M-CLL, showing only subtle differences in gene 
expression signatures in these clinically distinct subgroups 
(Klein et al., 2001; Rosenwald et al., 2001); along this line, 
one gene known to be up-regulated in U-CLL is ZAP70, 
and this gene also showed a higher expression in NFKBIE-
deleted patients. In addition, as constitutive NF-B activation 
has been observed in most, if not all, CLL patients, this may 
also override potential relevant yet subtler differences in gene 
expression between NFKBIE-deleted and WT patients.
Altered response to ibrutinib in NFKBIE-deleted cases
Finally, because truncating IB mutations appeared to lead 
to constitutive NF-B activation independent of BcR signal-
ing, we hypothesized that for NFKBIE-deleted patients no 
difference should be observed in the tumor cell response to 
for NFKBIE-deleted (n = 3) and WT (n = 2) samples, which 
revealed an increase in the nuclear fraction of p50 and p65 in 
NFKBIE-deleted patients (Fig. 5, A–D). Hence, loss of IB 
inhibitory function increased nuclear p50/p65 translocation 
and consequent NF-B activation.
NFKBIE deletion has limited impact  
on the global gene expression profile
To further investigate the impact of this truncating mutation, 
using shRNA, we knocked down the expression of IB (by 
56% and 60%, in two independent experiments) in the HG3 
CLL cell line (Rosén et al., 2012), which revealed differential 
gene expression profiles between the knockdowns and the 
parental as well as the mock-transfected cell line (Fig. 5, E and F; 
and Table S12). Gene annotation enrichment analysis using 
the DAVID Bioinformatics Resources revealed that the top an-
notation clusters included regulation of apoptosis and cell death 
and regulation of the NF-B signaling pathway (Table S13). 
Because the HG3 cell line is EBV transformed, which may 
seriously interfere with BcR signaling (Siemer et al., 2008), 
we next studied the global gene expression patterns in primary 
CLL cells from nine NFKBIE-deleted (mean allele frequency 
Figure 4. Interactions between IBs and p65 in CLL. (A) Co-IP to study the interaction between p65 and IB in NFKBIE-deleted (n = 3) versus WT 
(n = 2) CLL. The bottom panel indicates TCL from samples used in the co-IP assay. (B) Mean values for IB pull-down in NFKBIE-deleted versus WT CLL. 
(C) Proximity ligation assay to study the physical interaction between IB, IB and IB, and p65 in six NFKBIE WT CLL patients. Interactions were 
assessed in unstimulated (U), IgM-stimulated, and CD40L-stimulated cells. For IB and IB, six NFKBIE WT CLL patients were analyzed, whereas for 
IB only four NFKBIE WT CLL patients were assessed. (D) The interaction between IB and the transcription factor p65 in six NFKBIE WT CLL patients 
and six NFKBIE-deleted patients. Interactions were again assessed in unstimulated (U), IgM-stimulated, and CD40L-stimulated cells. Error bars indicate 
standard error. (E and F) Fluorescent microscope images of the interaction between IB and the transcription factor p65 in cells from a NFKBIE WT CLL 
patient (E) and an NFKBIE-deleted CLL patient (F). Blue color indicates cell nuclei, whereas each red dot represents a single interaction. Bars, 20 µm.
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the same lines, one could reasonably hypothesize that because 
of tonic BcR signaling, NFKBIE mutant CLL cases could 
be more dependent on external stimulation and, hence, more 
sensitive to BTK inhibition (Davis et al., 2010; Mathews 
Griner et al., 2014).
In summary, we provide for the first time a novel genetic 
basis for NF-B activation with the prime finding being re-
current mutations in genes belonging to the NF-B pathway 
and in particular within the NFKBIE gene not only in CLL 
but also in other B cell–derived malignancies. In CLL, we 
show that NFKBIE aberrations were highly enriched in 
poor-prognostic, stereotyped subsets, potentially contribut-
ing to their adverse prognosis, and resulted in reduced IB 
the BcR inhibitor ibrutinib after IgM stimulation. To test 
this hypothesis, we treated primary CLL cells from four 
NFKBIE-deleted and four NFKBIE WT patients with ibru-
tinib, in the presence or the absence of IgM stimulation. 
A difference in cell survival was observed between unstimulated 
versus stimulated IB-WT cells, whereas no such difference 
was seen in IB-mutated cases (Fig. 5 G), which were gener-
ally more sensitive to ibrutinib than WT patients. Although at 
first sight the finding that NFKBIE-deleted cases were gener-
ally more sensitive to ibrutinib than WT patients may seem 
counterintuitive, a similar observation has been reported for 
the ABC type of DLBCL and has been attributed to tonic 
activation of the BcR–NF-B signaling pathway. Thus, along 
Figure 5. Functional analysis of the NFKBIE deletion 
in CLL. (A) Cytoplasmic (C) and nuclear (N) expression of 
p50, p65, and PARP in CLL patients. For the nuclear fraction, 
the expression ratio to PARP is provided. (B) Expression 
levels for p50, p65, and GAPDH in TCLs for the same patient. 
Normalized nuclear expression for p50 and p65 is provided. 
(C and D) Mean normalized nuclear expression of p50 (C) and 
p65 (D) in CLL. Error bars indicate standard error. (E) Western 
blot showing IB expression for the mock-transfected cells 
as well as the two independent knockdown clones (KD c1 
and c2) in the HG3 cell line. All samples were run on the 
same gel but not in adjacent lanes and have therefore been 
quantified using the same exposure time. (F) Gene expression 
patterns in two independent CLL HG3 cell lines (c1 and c2) 
with partial knockdown (KD) of IB compared with the 
mock-transfected and untransfected (UT) HG3 cell lines. 
Genes that showed at least 50% difference in both c1 and c2 
compared with either Mock or UT were selected. The list of 
genes is provided in Table S12. (G) Dose–response curves to 
the BTK inhibitor ibrutinib in primary CLL samples with WT 
NFKBIE (n = 4) and deleted NFKBIE (n = 4). Data were nor-
malized against ibrutinib-naive CLL cells in culture. In NFKBIE 
WT cases, borderline significance was observed when com-
paring IgM-stimulated versus unstimulated cells (P = 0.07 
at 0.1 µM concentration, P = 0.06 at 1 µM concentration, 
and P = 0.05 at 2.5 µM concentration). Error bars indicate 
standard error.
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DNA Analyzer (Applied Biosystems) and analyzed with Peak Scanner Soft-
ware v1.0 (Applied Biosystems).
Western blots, co-IP assays, and cell fractions. Primary CLL cells 
were washed in PBS and lysed for 10 min in ice-cold RIPA buffer supple-
mented with phosphatase/protease inhibitors (Roche). Crude cell lysates were 
cleared by centrifugation and supernatants were transferred to new tubes. 
For collection of total cell lysates (TCLs), the supernatants were immediately 
mixed with 4× NuPAGE LDS sample buffer (Life Technologies) with DTT 
and treated at 95°C for 5 min. For co-IP assays, supernatants were first incu-
bated 2 h at 4°C (end-over-end rotation) with 1:100 addition of either 
an anti-p65 antibody (a detailed list of all antibodies used is provided in 
Table S15) or a non-p65–targeting control antibody (AML1) followed by 
addition of protein A agarose beads (Cell Signaling Technology) and an extra 
hour of incubation. Beads were collected by centrifugation and washed three 
times in ice-cold RIPA buffer before being diluted in NuPAGE LDS Sam-
ple buffer (Life Technologies) supplemented with DTT and heated at 95°C 
for 5 min. Nuclear and cytoplasmic cell fractions were obtained as previously 
described by Andrews and Faller (1991). Denatured samples were separated 
on NuPAGE Novex 4–12% Bis-Tris Gels (Life Technologies) and trans-
ferred to nitrocellulose membranes using iBlot (Life Technologies). Block-
ing was performed at room temperature by incubating membranes for 1 h in 
5% wt/vol nonfat dry milk (Bio-Rad Laboratories) or 5% wt/vol BSA 
(Sigma-Aldrich) in TBS buffer. Primary antibodies were diluted in TBS-T 
(0.1% Tween-20) with 5% wt/vol nonfat dry milk (Bio-Rad Laboratories) 
or 5% wt/vol BSA (Sigma-Aldrich) and were incubated together with the 
blocked membranes at 4°C over night. Before imaging, membranes were 
washed (3× 20 min) in TBS-T (0.1% Tween-20), incubated 1 h with sec-
ondary antibodies (1:10,000/1:20,000 of the IRDye 800CW goat anti– 
rabbit IgG and/or 1:20,000 of the IRDye 680RD donkey anti–mouse IgG 
[LI-COR Biosciences]) in TBS-T (0.1% Tween-20) with 5% wt/vol BSA, 
washed (3× 15 min) in TBS-T (0.1% Tween-20), and finally rinsed 5 min in 
TBS buffer only. All incubation steps were performed at room temperature. 
Membranes were scanned and imaged using the Odyssey CLx Infrared 
Imaging System (LI-COR Biosciences). Protein bands were quantified using 
ImageJ software (National Institutes of Health).
Stimulation of BcR and CD40 signaling pathways. Two million via-
ble primary CLL cells per milliliter were grown in RPMI medium supple-
mented with 10% FBS (Gibco), 1% PEST (Gibco), and 1% l-glutamate 
(Gibco), supplemented with 25% vol/vol serum-free supernatant from the 
T cell hybridoma cell line MP6 (Rosén et al., 1986), as a source of thioredoxin 
(Söderberg et al., 1999; Nilsson et al., 2000). For stimulation of the BcR, the 
modified RPMI medium was supplemented with 3 µg/ml AffiniPure F(ab)2 
fragment rabbit anti–human IgM (Jackson ImmunoResearch Laboratories, 
Inc.), 10 ng/ml IL-2 (GE Healthcare), and 1 µg/ml streptavidin (Roche). To 
stimulate the CD40 signaling pathway, cells were treated with the modified 
RPMI medium supplemented with 100 ng/ml sCD40L (Enzo Life Sci-
ences), 25 ng/ml IL-4 (R&D Systems), and 100 ng/ml IL-10 (R&D Sys-
tems). Cells were stimulated for 15 min at 37°C (5% CO2). Cytospins were 
prepared using 150,000 cells per slide and a Cellspin I cytocentrifuge (Thar-
mac) at 500 rpm for 2 min.
Proximity ligation assay. The cells were fixed in 3.7% formaldehyde so-
lution (Sigma-Aldrich) for 15 min at room temperature and permeabilized 
in 0.5% Triton X-100 (GE Healthcare) for 2 min at room temperature. All 
washing steps were performed twice for 5 min in 1× TBS with 0.05% 
Tween (Sigma-Aldrich) unless stated otherwise. First, the samples were in-
cubated in a blocking solution (Olink Biosciences) for 1 h at 37°C. The pri-
mary antibodies were diluted as follows, p65 (Cell Signaling Technology) 
1:400, IB (Cell Signaling Technology) 1:50, IB (Santa Cruz Biotech-
nology, Inc.) 1:50, IBE (Santa Cruz Biotechnology, Inc.) 1:200, and IB 
(Cell Signaling Technology) 1:50 in antibody diluent solution (Olink Bio-
sciences) and applied to the samples for incubation over night at 4°C. The 
samples were then washed and incubated with Duolink In Situ PLA Probe 
protein levels and diminished interactions between IB–p65, 
as well as increased p65 phosphorylation and nuclear transloca-
tion. Notably, minor clones and/or clonal evolution were also 
observed, thus potentially linking IB loss to disease progres-
sion. Considering the central role of BcR stimulation in the 
natural history of CLL, the functional loss of IB may sig-
nificantly contribute to sustained CLL cell survival in these 
patients. On these grounds, components of the NF-B signal-
ing pathway may emerge as possible targets for future therapies 
in CLL and, possibly, also other mature B cell lymphomas.
MATERIALS AND METHODS
Patient samples. In total, 692 CLL samples were collected from collaborat-
ing institutions in Sweden, Greece, Italy, France, Czech Republic, the 
Netherlands, the USA, and the UK. All cases were diagnosed according to 
the iwCLL criteria, displayed a typical CLL immunophenotype, and con-
tained >70% tumor cells (Hallek et al., 2008). Clinicobiological characteris-
tics of the discovery and validation cohorts are summarized in Tables S2 and 
S5. Mantle cell lymphoma (n = 136), DLBCL (n = 66), and splenic marginal 
zone lymphoma (n = 170) samples were diagnosed according to the WHO 
classification. The study was approved by the local Ethics Review Committees 
(Brno: NT13493-4/2012, Milan: VIVI-CLL, New York: 08-202A, Thessa-
loniki: CERTH/ETH2, Uppsala: 214/33, Southampton: 06/Q2202/30, 
and Stockholm: 2006/964-31/2).
Targeted enrichment and library construction. We applied HaloPlex 
technology (Agilent Technologies) for targeted enrichment. For the dis-
covery cohort, an earlier version of the current HaloPlex protocol was 
used. Biotin-labeled probes were designed for 18 NF-B genes that tar-
geted all coding exons with a high coverage (Tables S1 and S6). In brief, 
genomic DNA was fragmented using a combination of restriction en-
zymes. Biotin-labeled HaloPlex probes were hybridized to the target DNA 
and acted as template for a second universal DNA oligonucleotide, which 
contains primer sites, sequencing barcodes, and adapter sequences. The 
target DNA and the hybridized molecules were captured using streptavidin-
labeled magnetic beads and circularized after a ligation reaction. The cir-
cularized DNA was amplified using universal primers. For the validation 
cohort, we took advantage of the automated HaloPlex protocol (http://
www.chem.agilent.com/Library/usermanuals/Public/G9900-90020.pdf) 
using a Bravo Automated Liquid Handling Platform (Agilent Technolo-
gies). The libraries were subsequently sequenced using a HiSeq 2000 se-
quencing system (Illumina).
Targeted sequencing data analysis. Illumina adapters were trimmed using 
Cutadapt, and the reads were aligned to the human genome reference hg19/
NCBI GRCh37 using the MOSAIK alignment tool version 2.2 (Martin, 
2011). SAMTools was used for file format conversion and sorting. Using a 
modified version of GATK-lite, the aligned reads were mapped to their corre-
sponding HaloPlex fragment. Variants were detected using an in-house, 
purpose-built variant caller (SNPmania) and annotated using ANNOVAR 
(Wang et al., 2010). Exonic variants were kept if they fulfilled the following 
criteria: (a) having a variant allele ratio of ≥0.1, (b) not in dbSNP and/or 1,000 
genomes unless annotated in the Cosmic database, and (c) supported by at least 
two amplicons unless the position was covered by a single amplicon only.
Sanger sequencing and GeneScan analysis. Selected variants were sequenced 
using the BigDye Terminator v3.1 Cycle Sequencing kit and an ABI 3730 
DNA Analyzer (Life Technologies) using standard protocols. For GeneScan 
analysis, the following oligonucleotides were used for the analysis of the 4-bp de-
letion in NFKBIE: forward primer, 5-[Hex]CCTCAAAAGTGGGCTGAG-3; 
and reverse primer, 5-CAAGGAACCACAGGAGAAGG-3. Genomic 
DNA was amplified by hot-start PCR with Platinum-Taq DNA Polymerase 
(Invitrogen) and 60°C as annealing temperature. The fragment length of the 
PCR products was assessed by capillary electrophoresis with ABI3730XL 
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Statistical analysis. Paired Student’s t test was used to assess differences be-
tween subgroups with at least four patients in each subgroup. Friedman ANOVA 
was used to study differences in NFKBIE mutation frequency among CLL sub-
set cases. Kaplan-Meier analysis was performed to construct survival curves for 
TTFT, defined as the time interval from the diagnosis date until date of initial 
treatment, and the log-rank test was used to assess differences. All statistical analy-
ses were performed using Statistica version 12 (Stat Soft).
Online supplemental material. Table S1 shows the 18 NF-B core com-
plex genes targeted for deep sequencing in the discovery cohort. Table S2 
shows the clinical and biological characteristics of CLL patients in the dis-
covery cohort. Table S3 shows a summary of mutations found in the dis-
covery cohort (n = 124) with additional molecular data. Table S4 shows 
low-frequency NFKBIE deletions (<10%) detected in the discovery (n = 124) 
and validation cohorts (n = 191). Table S5 shows clinical and biological 
characteristics of CLL patients in the validation cohort. Table S6 shows the 
18 NF-B core complex genes targeted for deep sequencing in the valida-
tion cohort. Table S7 shows a summary of mutations found in the validation 
cohort (n = 191). Table S8 shows clinical and biological characteristics of the 
population-based CLL cohort. Table S9 shows a summary of NFKBIE dele-
tions detected by GeneScan analysis (n = 383). Table S10 shows multivariate 
analyses for TTFT (A) and for TTFT excluding IGHV mutation status (B). 
Table S11 shows allelic ratio of the deleted NFKBIE allele detected by Gene-
Scan analysis. Table S12 shows differentially expressed genes in the HG3 
cell line after NFKBIE knockdown. Table S13 shows gene annotation en-
richment analysis, performed using the DAVID Bioinformatics Resources 
for differentially expressed genes in HG3 cell line after NFKBIE knock-
down. Table S14 shows a list of significantly differentially expressed genes in 
NFKBIE-deleted versus NFKBIE WT cases. Table S15 shows the list of anti-
bodies used. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20142009/DC1.
Sequencing was performed by the SNP&SEQ Technology Platform, Science for 
Life Laboratory at Uppsala University, a national infrastructure supported by the 
Swedish Research Council (VRRFI) and the Knut and Alice Wallenberg Foundation. 
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anti–mouse MINUS Affinity donkey anti–mouse IgG and Duolink In Situ 
PLA Probe anti–rabbit PLUS Affinity donkey anti–rabbit IgG (Olink Biosci-
ence) diluted 1:5 in antibody diluent solution (Olink Biosciences) for 1 h at 
37°C, followed by washing. A hybridization solution containing 0.25 mg/ml 
BSA (New England Biolabs, Inc.), 25 mM NaCl, 0.05% Tween-20 
(Sigma-Aldrich), 10 mM TrisAc, 10 mM MgAc, 50 mM KAc, and 125 nM 
of circularization oligonucleotides (5-GTTCTGTCATATTTAAGC-
GTCTTAA-3 and 5-CTATTAGCGTCCAGTGAATGCGAGTCCGT-
CTAAGAGAGTAGTACAGCAGCCGTCAAGAGTGTCTA-3; Integrated 
DNA Technology) at pH 7.5 were applied to the sample for 30 min incuba-
tion at 37°C, followed by washing. Both oligonucleotides were phosphory-
lated in the 5 end. Ligation of the circularization oligonucleotides were 
performed in 1× T4 ligation buffer (Fermentas, Thermo Fisher Scientific), 
0.05 U/µl T4 DNA ligase (Fermentas), and ddH2O for 30 min at 37°C, fol-
lowed by washing. Rolling circle amplification was performed by incubating 
the samples in 0.25 mg/ml BSA (New England Biolabs, Inc.), 300 ng/ml 
poly-adenosine, 1× phi29 DNA polymerase buffer (Fermentas), 0.25 mM 
dNTP (Thermo Fisher Scientific), 1 µM Hoechst 33342 (Sigma-Aldrich), 
0.25 U/µl phi29 DNA polymerase (Fermentas), and a BODIPY TR–labeled 
oligonucleotide (5-CAGTGAATGCGAGTCCGTCTUUUU-3, U rep-
resents Uracil 2 O methyl RNA group; Trilink) for 90 min at 37°C. Finally, 
the samples were washed twice in 1× TBS supplemented with Tween 
(Sigma-Aldrich) and once in 1× TBS, followed by centrifugation of the 
slides. SlowFade Gold antifade reagent (Life Technologies) was used for 
mounting of the slides. Images were acquired with an Axioplan 2 imaging 
microscope (Carl Zeiss) using 40× objectives and an AxioCam MRm cam-
era (Carl Zeiss). Exposure times, number of z-levels, and distance between 
z-levels were kept the same for all patients within each assay. CellProfiler 
version one was used to quantify number of signals per cell in raw images. 
The interactions between the IBs and p65 were normalized against the 
number of interactions between p65 and p50 for each sample.
Stable knockdown of IB. Stable knockdown of IB in the HG3 CLL 
cell line was established using the pGIPZ lentiviral vector (V3LHS_365665) 
and the mature antisense sequence 5-TGGTCCAGATGTACAGCCA-3 
(GE Healthcare). The plasmid was linearized using Ssp1 restriction enzyme 
(Fermentas). HG3 cells were transfected with 3 µg of plasmid DNA per 107 
cells by electroporation using the Neon Transfection System (Thermo Fisher 
Scientific) and standard parameters. Puromycin selection was started 48 h 
after transfection and cells were kept under Puromycin selection. Additional 
selection for positive clones was performed by FACS sorting for cells ex-
pressing tGFP, expressed from the same promoter as the shRNA and the 
Puromycin resistance gene.
Gene expression analysis. Gene expression was studied using Affymetrix 
GeneChip Human Gene 2.0 ST Arrays (Affymetrix) and 250 ng total RNA 
according to standard protocols. Data were analyzed in R (The R Project for 
Statistical Computing) using packages from the Bioconductor project and 
normalized using the robust multi-array average method (Irizarry et al., 
2003). To search for differentially expressed genes, an empirical Bayes- 
moderated Student’s t test was applied using the “limma” package. The p-values 
were adjusted using the method of Benjamini and Hochberg to address po-
tential problems with multiple testing (Benjamini and Hochberg, 1995). 
Genes with an adjusted p-value <0.05 were regarded as differentially ex-
pressed. Gene annotation enrichment analysis was performed using the DAVID 
Bioinformatics Resources.
Ibrutinib treatment and cell viability test. Unstimulated and IgM- 
stimulated (10 µg/ml for 15 min) primary CLL cells from four NFKBIE WT 
patients and four NFKBIE-deleted patients were plated in quadruplicate wells 
at a density of 100,000 cells per well in 96-well plates followed by ibrutinib 
(PCI-32765; Selleckchem) treatment at 0, 0.1, 1, 2.5, and 10 µM concentration 
for 72 h. Alamar Blue (Life Technologies) was added, and cell viability was 
measured after 24 h using a VICTOR plate reader (PerkinElmer) and standard 
protocols. Data were normalized against ibrutinib naive matched controls.
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